Skip to main content
Premium Trial:

Request an Annual Quote

Larry Stambaugh, John Petrovich, Betsy McCaughey

Premium
Arrowhead Research said this week that it has appointed Larry Stambaugh as president and CEO of its Calando Pharmaceuticals and Insert Therapeutics subsidiaries, which are expected to be merged.
 
Calando is developing RNAi-based treatments for cancer (see RNAi News, 3/22/2007). Insert is focused on developing a proprietary delivery system for small molecule- and nucleic acid-based cancer drugs.
 
Stambaugh will replace John Petrovich, who has been serving as the CEO of both Calando and Insert, will remain as executive vice president of both companies and of the combined company when the merger is completed.
 
Stambaugh was previously the chairman and CEO of Maxim Pharmaceuticals. He holds a BBA from Washburn University and is a certified public accountant, Arrowhead said.
 

 
Antisense drug developer Genta said that Betsy McCaughey has resigned from the company’s board.
 
She served on Genta’s board since 2001.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.